3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
8
Phase 3
5
Phase 2
4
Phase 1/2
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
410
Cyclophosphamide
394
Carboplatin
306
Gemcitabine
286
Nivolumab
276
Paclitaxel
274
Cisplatin
252
Radiotherapy
225
Dexamethasone
210
Bevacizumab
209
fludarabine
192
Docetaxel
187
Rituximab
183
Capecitabine
171
Oxaliplatin
158
Lenalidomide
157
Fluorouracil
152
Temozolomide
138
Cytarabine
135
Etoposide
128
Irinotecan
124
Cetuximab
123
fludarabine phosphate
120
Injections
118
venetoclax
116
Ipilimumab
115
Doxorubicin
114
Azacitidine
108
130-nm albumin-bound paclitaxel
108
Pemetrexed
107
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Interventional
×
AZD9833
×
Clear all
NCT06188520
2026-05-11
CYCAD-1
AstraZeneca
Phase 1/2
Recruiting
564 enrolled
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled